000182834 001__ 182834
000182834 005__ 20240229145732.0
000182834 0247_ $$2doi$$a10.1016/j.vaccine.2022.11.044
000182834 0247_ $$2pmid$$apmid:36446654
000182834 0247_ $$2ISSN$$a0264-410X
000182834 0247_ $$2ISSN$$a1358-8745
000182834 0247_ $$2ISSN$$a1873-2518
000182834 0247_ $$2altmetric$$aaltmetric:139511725
000182834 037__ $$aDKFZ-2022-02961
000182834 041__ $$aEnglish
000182834 082__ $$a610
000182834 1001_ $$aJoshi, Smita$$b0
000182834 245__ $$aEvaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.
000182834 260__ $$aAmsterdam$$bElsevier$$c2023
000182834 3367_ $$2DRIVER$$aarticle
000182834 3367_ $$2DataCite$$aOutput Types/Journal article
000182834 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677577839_27831
000182834 3367_ $$2BibTeX$$aARTICLE
000182834 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182834 3367_ $$00$$2EndNote$$aJournal Article
000182834 500__ $$aVolume 41, Issue 1, 4 January 2023, Pages 236-245
000182834 520__ $$aThe recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10 years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women.Participants received at age 10-18 years either one, two or three doses of the quadrivalent HPV vaccine. Serology samples were obtained at different timepoints up to 10 years after vaccination from a convenience sample of vaccinated participants and from age-matched unvaccinated women at one timepoint. The evolution of the binding and neutralizing antibody response was presented by dose received. 10-year durability of immune responses induced by a single-dose was compared to that after three doses of the vaccine and in unvaccinated married women.The dynamics of antibody response among the single-dose recipients observed over 120 months show stabilized levels 18 months after vaccination for all four HPV types. Although the HPV type-specific (binding or neutralizing) antibody titres after a single-dose were significantly inferior to those after three doses of the vaccine (lower bounds of GMT ratios < 0.5), they were all significantly higher than those observed in unvaccinated women following natural infections (GMT ratios: 2.05 to 4.04-fold higher). The results correlate well with the high vaccine efficacy of single-dose against persistent HPV 16/18 infections reported by us earlier at 10-years post-vaccination.Our study demonstrates the high and durable immune response in single-dose recipients of HPV vaccine at 10-years post vaccination.
000182834 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182834 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182834 650_7 $$2Other$$aHuman papillomavirus
000182834 650_7 $$2Other$$aNatural immunity
000182834 650_7 $$2Other$$aSingle dose
000182834 650_7 $$2Other$$aVaccine immune responses
000182834 650_7 $$2Other$$aquadrivalent HPV vaccine
000182834 7001_ $$aAnantharaman, Devasena$$b1
000182834 7001_ $$aMuwonge, Richard$$b2
000182834 7001_ $$aBhatla, Neerja$$b3
000182834 7001_ $$aPanicker, Gitika$$b4
000182834 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia Anna$$b5$$udkfz
000182834 7001_ $$aRani Reddy Poli, Usha$$b6
000182834 7001_ $$aMalvi, Sylla G$$b7
000182834 7001_ $$aEsmy, Pulikkottil O$$b8
000182834 7001_ $$aLucas, Eric$$b9
000182834 7001_ $$aVerma, Yogesh$$b10
000182834 7001_ $$aShah, Anand$$b11
000182834 7001_ $$aZomawia, Eric$$b12
000182834 7001_ $$aPimple, Sharmila$$b13
000182834 7001_ $$aJayant, Kasturi$$b14
000182834 7001_ $$aHingmire, Sanjay$$b15
000182834 7001_ $$aChiwate, Aruna$$b16
000182834 7001_ $$aDivate, Uma$$b17
000182834 7001_ $$aVashist, Shachi$$b18
000182834 7001_ $$aMishra, Gauravi$$b19
000182834 7001_ $$aJadhav, Radhika$$b20
000182834 7001_ $$aSiddiqi, Maqsood$$b21
000182834 7001_ $$aSankaran, Subha$$b22
000182834 7001_ $$aPillai Rameshwari Ammal Kannan, Thiraviam$$b23
000182834 7001_ $$aKartha, Purnima$$b24
000182834 7001_ $$aShastri, Surendra S$$b25
000182834 7001_ $$aSauvaget, Catherine$$b26
000182834 7001_ $$aRadhakrishna Pillai, M.$$b27
000182834 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b28$$udkfz
000182834 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b29$$udkfz
000182834 7001_ $$0P:(DE-He78)219d54a7bf634121fbf16bea82d434e1$$aSehr, Peter$$b30$$udkfz
000182834 7001_ $$aUnger, Elizabeth R$$b31
000182834 7001_ $$aSankaranarayanan, Rengaswamy$$b32
000182834 7001_ $$aBasu, Partha$$b33
000182834 773__ $$0PERI:(DE-600)1468474-3$$a10.1016/j.vaccine.2022.11.044$$gp. S0264410X22014578$$n4$$p236-245$$tVaccine$$v1$$x0264-410X$$y2023
000182834 909CO $$ooai:inrepo02.dkfz.de:182834$$pVDB
000182834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b28$$kDKFZ
000182834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000182834 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)219d54a7bf634121fbf16bea82d434e1$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000182834 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182834 9141_ $$y2022
000182834 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000182834 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000182834 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000182834 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000182834 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVACCINE : 2022$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000182834 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bVACCINE : 2022$$d2023-10-21
000182834 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x0
000182834 9201_ $$0I:(DE-He78)W040-20160331$$kW040$$lGruppe Sehr EMBL$$x1
000182834 980__ $$ajournal
000182834 980__ $$aVDB
000182834 980__ $$aI:(DE-He78)F020-20160331
000182834 980__ $$aI:(DE-He78)W040-20160331
000182834 980__ $$aUNRESTRICTED